Picard Medical Q1 Revenue Soars 79.9% to $1.1M on STAH Demand
Picard Medical’s preliminary Q1 revenue rose 79.9% to $1.1 million, driven by higher SynCardia Total Artificial Heart utilization and increased driver rental income. Pricing adjustments and favorable U.S. reimbursement conditions supported the revenue gain compared to $0.6 million in Q1 2025.
1. Q1 Revenue Jumped 79.9%
Picard Medical reported preliminary unaudited revenues of $1.1 million for the quarter ended March 31, 2026, marking a 79.9% increase from $0.6 million in the same period last year.
2. Growth Driven by STAH Demand and Pricing
The revenue surge reflected higher utilization of the SynCardia Total Artificial Heart as a bridge to transplant and increased driver rental income following pricing adjustments and favorable U.S. reimbursement conditions.
3. Outlook and Reporting Timeline
The company will finalize and file its audited Q1 results in a 10-Q by May 15, 2026, while continuing development of its next-generation fully implantable total artificial heart platform.